Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 12/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.42 |
| ▸ | IGF1R | P08069 | 4/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353143 | 0.81 | MEN1 (0.51) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL28429000 | 0.77 | PLK4 (0.56) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL30353159 | 0.77 | MEN1 (0.47) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL30353160 | 0.77 | MEN1 (0.47) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL30353126 | 0.74 | MEN1 (0.50) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL30353156 | 0.73 | MEN1 (0.44) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL17383410 | 0.73 | MEN1 (0.42) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL30353167 | 0.73 | MEN1 (0.56) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL20575194 | 0.72 | MEN1 (0.55) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL25472741 | 0.71 | MEN1 (0.54) | MEN1HTTKMT2AHSD17B10AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | MEN1 3546/4885HTT 3372/4885KMT2A 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.